AstraZeneca to buy fusion for $2 billion

​​The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis' treatment showed that the drug extended survival for prostate cancer patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news